<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03721406</url>
  </required_header>
  <id_info>
    <org_study_id>ROPICTPVB</org_study_id>
    <nct_id>NCT03721406</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic of Thoracic Paravertebral Ropivacaine</brief_title>
  <official_title>The Pharmacokinetic of Ropivacaine in Patients Undergoing Ultrasound-guided Continuous Thoracic Paravertebral Block</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Attikon Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Attikon Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to investigate the pharmacokinetic of ropivacaine in patients undergoing&#xD;
      ultrasound guided thoracic paravertebral block (TPVB) both after a single-bolus injection via&#xD;
      the thoracic paravertebral catheter given before the start of surgery and after continuous&#xD;
      thoracic paravertebral infusion that will start after the end of the procedure in order to&#xD;
      achieve postoperative analgesia after open thoracotomy during the first 3 postoperative days&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients aged &gt;18yrs, of ASA I-III undergoing open thoracotomy under combined ultrasound&#xD;
      guided thoracic paravertebral block (TPVB) and general anesthesia will be enrolled in the&#xD;
      study.&#xD;
&#xD;
      TPVB will be performed under ultrasound guidance on the side of the operation immediately&#xD;
      after induction of anesthesia and patient intubation, with the patient in the lateral&#xD;
      position at the T5 or T6 or T7 thoracic level using a Tuohy 17G needle and the catheter will&#xD;
      be advanced 5 cm beyond the point of needle tip.&#xD;
&#xD;
      Dosage regimen Initially, after catheter placement and control, 0.5% ropivacaine is&#xD;
      administered via the catheter in a 25 ml single dose, before the start of surgery.&#xD;
&#xD;
      After the end of surgery and patient awakening, the catheter will be connected with an&#xD;
      electronic pump and the continuous infusion of ropivacaine 0.2% will start with a constant&#xD;
      infusion rate of 14 ml/h for the first 3 postoperative days.&#xD;
&#xD;
      Postoperative pain will be assessed using the Visual Analogue Scale (VAS: 0-10).&#xD;
      Postoperative analgesia will be managed with continuous PVB, and systemic administration of&#xD;
      paracetamol (1 gr X 4 iv), tramadol (100 mg x 3 iv) and pregabalin (75 mg x 2 pos).&#xD;
      Additionally, if VAS is ≥4-5 morphine (2.5 -5mg) will be administered subcutaneously as&#xD;
      rescue analgesic drug (max 6 doses/day). In case of persistent pain (VAS &gt; 4-5) despite the&#xD;
      previously mentioned treatment measures, PCA morphine will be used.&#xD;
&#xD;
      Postoperative data include arterial blood pressure, heart rate, SpO2, VAS scores, clinical&#xD;
      signs of local anesthetic toxicity during the first 3 postoperative days, specifically at 12,&#xD;
      24, 36, 48 and 72 postoperative hours.&#xD;
&#xD;
      Samples Serial blood samples from radial artery and central venous line will be collected at&#xD;
      predefined time points, as following.&#xD;
&#xD;
      After the single-dose paravertebral injection Serial blood samples from radial artery will be&#xD;
      collected at 5, 7.5, 10, 15, 20, end of surgery (min) Serial blood samples from central&#xD;
      venous line will be collected at 1, 5, 7.5, 10, 15, 20, 40, 60, end of surgery (min)&#xD;
&#xD;
      After the initiation of continuous paravertebral infusion Serial blood samples from radial&#xD;
      artery will be collected at 2.5, 7.5, 15, 30, 60 (min) and afterwards at 24, 48, 72 (hours)&#xD;
      Serial blood samples from central venous line will be collected at 2.5, 10, 15, 30, 60 (min)&#xD;
      and afterwards at 2, 6, 24, 48, 72 (hours)&#xD;
&#xD;
      Determination of ropivacaine plasma levels samples collected at regular intervals. All blood&#xD;
      samples (2.5ml) will be placed into EDTA vacutainer tubes and immediately centrifuged&#xD;
      (3,500rpm, 10min) after which the plasma will be Ropivacaine plasma levels will be measured&#xD;
      in both arterial and venous blood removed. Plasma samples will be stored at -70 ° C until&#xD;
      assayed. Bioassay of blood samples will be performed according to Good Laboratory Practice.&#xD;
&#xD;
      Measurement of ropivacaine plasma concentrations Quantification of total ropivacaine plasma&#xD;
      levels in blood samples (sample volume 1mL) will be performed by high performance liquid&#xD;
      chromatography (HPLC), using the method developed by Gaudreault F, Drolet P and Varin F&#xD;
      (2009)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 8, 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">February 25, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ropivacaine plasma levels</measure>
    <time_frame>up to 72 postoperative hours after the initiation of continuous thoracic paravertebral infusion of ropivacaine</time_frame>
    <description>Ropivacaine plasma levels in both arterial and venous blood samples collected at regular intervals</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical signs of local anesthetic toxicity</measure>
    <time_frame>Up to 72 hours after the initiation of continuous thoracic paravertebral infusion of ropivacaine</time_frame>
    <description>Cardiac arrythmia on ECG</description>
  </secondary_outcome>
  <other_outcome>
    <measure>VAS scores</measure>
    <time_frame>up to 72 postoperative hours after the initiation of continuous thoracic paravertebral infusion of ropivacaine</time_frame>
    <description>Postoperative pain will be assessed using the Visual Analogue Scale (0-10cm, 0=no pain, 10=the worst pain)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Open Thoracotomy</condition>
  <arm_group>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>25 ml single dose of 0.5% ropivacaine&#xD;
continuous infusion of ropivacaine 0.2% with a constant infusion rate of 14 ml/h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>ropivacaine administerd via thoracic paraveretebral catheter</description>
    <arm_group_label>Ropivacaine</arm_group_label>
    <other_name>thoracic paravertebral block</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  ASA I-III&#xD;
&#xD;
          -  Open thoracotomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Morbid obesity&#xD;
&#xD;
          -  Scoliosis&#xD;
&#xD;
          -  Previous thoracotomy&#xD;
&#xD;
          -  Empyema&#xD;
&#xD;
          -  Drug allergy&#xD;
&#xD;
          -  Severe systemic disease&#xD;
&#xD;
          -  ASA &gt; III&#xD;
&#xD;
          -  Hypoalbuminemia&#xD;
&#xD;
          -  Urgent surgery&#xD;
&#xD;
          -  Reoperation during the study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paraskevi K Matsota, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>2nd Department of Anaesthesiology, &quot;Attikon&quot; University Hospital, Athens</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>2nd Department of Anesthesiology, Attikon University Hospital</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paraskevi K Matsota</name>
      <address>
        <city>Athens</city>
        <state>Other</state>
        <zip>13231</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 23, 2018</study_first_submitted>
  <study_first_submitted_qc>October 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2018</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Attikon Hospital</investigator_affiliation>
    <investigator_full_name>Paraskevi Matsota</investigator_full_name>
    <investigator_title>Assoc Prof of Anaesthesiology</investigator_title>
  </responsible_party>
  <keyword>ropivacaine</keyword>
  <keyword>undergoing ultrasound guided thoracic paravertebral block</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

